Search research articles
Contact Us
Filters
Showing results (31-40 of 168) with videos related to
Page
of 17
Sort By:
British Journal of Haematology
|
August 7, 2012
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
William Bensinger, Richard T Maziarz, Sundar Jagannath, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 2, 2014
R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma
Zachary Frosch, Marlise R Luskin, Daniel J Landsburg, et al.
American Journal of Hematology
|
August 3, 2013
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma
Ivana N Micallef, Patrick J Stiff, Edward A Stadtmauer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 12, 2012
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial
Auayporn P Nademanee, John F DiPersio, Richard T Maziarz, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 22, 2019
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Jatin Shah, Saad Usmani, Edward A Stadtmauer, et al.
Leukemia & Lymphoma
|
August 20, 2005
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation
Dan T Vogl, Eli Glatstein, Joseph R Carver, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 4, 2010
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma
Patrick J Stiff, Ivana Micallef, Auayporn P Nademanee, et al.
Cancer
|
June 22, 2010
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
Meletios Dimopoulos, Adrian Alegre, Edward A Stadtmauer, et al.
British Journal of Haematology
|
September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
Dan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
JAMA Oncology
|
December 30, 2017
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
Adam J Waxman, Suparna Clasen, Wei-Ting Hwang, et al.
Page
of 17
Search research articles
Search
Showing results (31-40 of 168) with videos related to
Sort By:
Page
of 17
British Journal of Haematology
|
August 7, 2012
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
William Bensinger, Richard T Maziarz, Sundar Jagannath, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 2, 2014
R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma
Zachary Frosch, Marlise R Luskin, Daniel J Landsburg, et al.
American Journal of Hematology
|
August 3, 2013
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma
Ivana N Micallef, Patrick J Stiff, Edward A Stadtmauer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 12, 2012
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial
Auayporn P Nademanee, John F DiPersio, Richard T Maziarz, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 22, 2019
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Jatin Shah, Saad Usmani, Edward A Stadtmauer, et al.
Leukemia & Lymphoma
|
August 20, 2005
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation
Dan T Vogl, Eli Glatstein, Joseph R Carver, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 4, 2010
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma
Patrick J Stiff, Ivana Micallef, Auayporn P Nademanee, et al.
Cancer
|
June 22, 2010
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
Meletios Dimopoulos, Adrian Alegre, Edward A Stadtmauer, et al.
British Journal of Haematology
|
September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
Dan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
JAMA Oncology
|
December 30, 2017
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
Adam J Waxman, Suparna Clasen, Wei-Ting Hwang, et al.
Page
of 17